Table 3.

Time to alleviation of symptoms for the intent-to-treat infected population

Population and treatment (n)Median time to alleviation (h) (95% CI)Hazard ratio (97.5% CI)a
Overall
    Peramivir
        300 mg (364)78.0 (68.4, 88.6)0.946 (0.793, 1.129)b
        600 mg (362)81.0 (72.7, 91.5)0.970 (0.814, 1.157)b
    Oseltamivir (365)81.8 (73.2, 91.1)
A/H1
    Peramivir
        300 mg (197)80.2 (69.3, 90.6)0.854 (0.672, 1.085)
        600 mg (200)83.6 (72.7, 101.9)0.927 (0.730, 1.176)
    Oseltamivir (201)88.8 (73.1, 102.2)
A/H3
    Peramivir
        300 mg (112)69.9 (54.4, 97.1)1.039 (0.745, 1.448)
        600 mg (108)70.6 (47.7, 91.9)0.958 (0.687, 1.335)
    Oseltamivir (108)75.1 (63.4, 92.6)
B
    Peramivir
        300 mg (21)55.3 (43.9, 86.4)0.445 (0.202, 0.982)
        600 mg (26)92.8 (57.4, 116.1)0.706 (0.341, 1.460)
    Oseltamivir (23)92.7 (70.2, 138.5)
  • a Hazard ratios compared to the oseltamivir group were estimated using Cox proportional-hazards models, which were adjusted for current smoking behavior, composite symptom score at baseline, country/region, influenza virus type, sex, complications, and previous therapy.

  • b Both peramivir groups were noninferior to the oseltamivir group, with a noninferiority margin of 0.170.